Study of Dietary Additive Phosphorus on Proteinuria and Fibroblast Growth Factor-23
Status: | Completed |
---|---|
Conditions: | Endocrine, Endocrine |
Therapuetic Areas: | Endocrinology |
Healthy: | No |
Age Range: | 21 - Any |
Updated: | 11/22/2017 |
Start Date: | January 2014 |
End Date: | September 2015 |
Randomized Cross-over Study Examining the Effects of Phosphorus Additives on Urinary Albumin Excretion and Fibroblast Growth Factor-23
Phosphorus-based food additives are commonly used by food manufacturers for many
applications, such as enhancing flavor, in ready-to-eat foods and beverages. While these
additives can significantly increase an individual's daily phosphorus intake, little is known
about the effect of dietary phosphorus on kidney health. In this study, the investigators
will first lower baseline phosphorus intake to about 1000mg/d by educating participants to
avoid foods with phosphorus additives. Then, participants will be randomized to a higher
phosphorus period (~2gm/d) and a lower phosphorus period (~1gm/d) by providing unaltered,
commercially-available food/beverage products with and without phosphorus additives.
The investigators hypothesize that participants will have higher urine albumin excretion and
fibroblast growth factor-23 during the higher phosphorus period compared to the lower
phosphorus period.
applications, such as enhancing flavor, in ready-to-eat foods and beverages. While these
additives can significantly increase an individual's daily phosphorus intake, little is known
about the effect of dietary phosphorus on kidney health. In this study, the investigators
will first lower baseline phosphorus intake to about 1000mg/d by educating participants to
avoid foods with phosphorus additives. Then, participants will be randomized to a higher
phosphorus period (~2gm/d) and a lower phosphorus period (~1gm/d) by providing unaltered,
commercially-available food/beverage products with and without phosphorus additives.
The investigators hypothesize that participants will have higher urine albumin excretion and
fibroblast growth factor-23 during the higher phosphorus period compared to the lower
phosphorus period.
Inclusion Criteria:
Adults at least 21 years of age with at least microalbuminuria
Exclusion Criteria:
Estimated glomerular filtration rate <45ml/min/1.73m2, poorly controlled diabetes or
hypertension, nephrotic syndrome, hyperparathyroidism, Paget's Disease, multiple myeloma,
uncontrolled thyroid disease, chronic antacid use, use of phosphorus binders, phosphorus
supplements, or high-dose vitamin D, inability to complete feeding study, investigator
discretion
We found this trial at
1
site
Click here to add this to my saved trials